Ipsen revamps U.S. sales ops for new cancer push; Gilead taps Mylan to sell HIV meds in India; Noven signs up to market hot-flash drug Brisdelle;

>Ipsen is setting up its own U.S. oncology team to market Somatuline, an acromegaly treatment, for potential new cancer indications; the French drugmaker's CEO will personally oversee the effort, with the help of a newly hired chief of endocrinology and oncology, Cynthia Schwalm. Report

> Gilead Sciences ($GILD) signed up U.S.-based Mylan ($MYL) to market its HIV treatments Viread, Truvada, and Stribild in India, where the U.S.-based generics maker has been expanding production and marketing. Report

> Noven, the U.S. unit of Hisamitsu Pharmaceutical, signed on to co-promote Brisdelle, the recently approved remedy for hot flashes from Shionogi. Report

> ViiV Healthcare, the HIV-oriented joint venture between GlaxoSmithKline ($GSK) and Pfizer ($PFE), launched its new drug Tivicay in the U.K.; it lacks public funding there yet, so for now it's available via private prescription. Report

> New guidances expected this year from the FDA and the HHS Office of Inspector General stand to affect both drug marketing and research. Report

> Biogen Idec ($BIIB) will be gearing up to launch its multiple sclerosis drug in Europe now that regulators there have approved the treatment. Report

> U.K. regulators green-lighted Allergan's ($AGN) Botox injection to treat ankle disability in stroke patients. Report

And Finally... Do patients want biopharma to be part of their social media conversations? Report

Suggested Articles

Horizon Therapeutics is preparing for the potential launch of inflammatory eye drug teprotumumab with team building.

Sanofi’s chief digital officer isn’t surprised to see CDOs popping up across Big Pharma. But they have to earn their keep, he says.

In a head-to-head against Bayer's Nexavar, Opdivo failed to significantly extend patients' lives in newly diagnosed liver cancer patients.